Rewalk Robotics (RWLK) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Rewalk Robotics (NASDAQ:RWLK) from a buy rating to a hold rating in a research note released on Thursday.
According to Zacks, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. “
RWLK has been the subject of a number of other reports. Oppenheimer set a $3.00 price target on Rewalk Robotics and gave the company a buy rating in a report on Tuesday, December 26th. Jefferies Group lowered their price target on Rewalk Robotics from $8.00 to $5.00 and set a buy rating for the company in a report on Friday, November 3rd. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $3.00 price target on shares of Rewalk Robotics in a report on Monday, November 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $2.83.
Shares of Rewalk Robotics (RWLK) traded down $0.02 on Thursday, reaching $1.10. The company had a trading volume of 207,542 shares, compared to its average volume of 459,682. The company has a debt-to-equity ratio of 7.46, a current ratio of 2.02 and a quick ratio of 1.65. The firm has a market capitalization of $31.82, a P/E ratio of -0.69 and a beta of 0.79. Rewalk Robotics has a 52-week low of $1.05 and a 52-week high of $3.60.
Rewalk Robotics (NASDAQ:RWLK) last announced its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.10. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.63 million. Rewalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.62) earnings per share. equities research analysts predict that Rewalk Robotics will post -1.14 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of RWLK. Renaissance Technologies LLC boosted its holdings in shares of Rewalk Robotics by 61.7% in the first quarter. Renaissance Technologies LLC now owns 78,600 shares of the medical device company’s stock valued at $165,000 after acquiring an additional 30,000 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of Rewalk Robotics by 328.7% in the third quarter. Essex Investment Management Co. LLC now owns 156,981 shares of the medical device company’s stock valued at $228,000 after acquiring an additional 120,362 shares during the period. Finally, Advisor Group Inc. boosted its holdings in shares of Rewalk Robotics by 1,495.6% in the third quarter. Advisor Group Inc. now owns 181,900 shares of the medical device company’s stock valued at $264,000 after acquiring an additional 170,500 shares during the period. 3.23% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Rewalk Robotics (RWLK) Downgraded by Zacks Investment Research” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/rewalk-robotics-rwlk-downgraded-by-zacks-investment-research/1798964.html.
About Rewalk Robotics
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with Analyst Ratings Network's FREE daily email newsletter.